Torisel among new approval recommendations in Japan
This article was originally published in Scrip
Executive Summary
Wyeth/Pfizer's infused mTOR kinase inhibitor, Torisel (temsirolimus), has been recommended for approval in Japan for the treatment of advanced renal cell carcinoma (RCC).